Full Press Release Details
Tiziana Life Sciences Plc
("Tiziana" or the "Company")
Exercise of options, Issue of Equity
PDMR Dealing and Total Voting Rights
London, New York, 26 October 2020
- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology
company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted
and issued 329,225 ordinary shares of 3 pence each ("New Ordinary Shares") credited as fully paid at a price of
35 pence per share in respect of the exercise of 329,225 options with an exercise price of 35 pence held by option holders, including
169,225 held by Gabriele Cerrone, Executive Chairman of the Company and 5,000 held by Keeren Shah, Finance Director of the Company.
The aggregate interests of Mr Cerrone in shares and voting rights accordingly increase by 169,225 shares to 66,224,893 representing
approximately 34.16% of the enlarged issued share capital. This is within the 1% increase threshold permitted pursuant to Note
11 to Rule 9 of the UK Takeover Code.
Application has been made for the 329,225
New Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings are expected to commence on or
around 29 October 2020. The New Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.
In conformity with DTR 5.6.1, the Company
notifies that as at the date of this announcement, it has a single class of shares in issue being Ordinary Shares and that following
the issue of the New Ordinary Shares to be issued in connection with the conversion of his loan notes, the total number of Ordinary
Shares in issue will be 193,841,726. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to
a single vote at general meetings of the Company.
The figure of 193,841,726 Ordinary Shares
may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will
determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed
(NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat
human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating
phase 2 studies with orally administered foralumab for Crohn's Disease and nasally administered foralumab for progressive
multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.
This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn's
Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
This announcement contains inside information
for the purposes of Article 7 of EU Regulation 596/2014. The person who arranged the release of this information is Keeren Shah,
Finance Director of Tiziana.
For further enquiries:
United Kingdom Investors:
| Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder | +44 (0)20 7495 2379 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner | +44 (0)20 7213 0880 |
| Optiva Securities Limited (Broker) Robert Emmet | + 44 (0)20 3981 4173 |
United States Investors:
Notification and public disclosure of
transactions by Persons Discharging Managerial Responsibilities ("PDMR")
and persons closely associated with them ("PCA")
| 1. | Details of PDMR / person closely associated | |
| a) | Name | (i) Gabriele Cerrone (ii) Keeren Shah |
| 2. | Reason for the notification | |
| a) | Position / status | (i) Executive Chairman (ii) Finance Director |
| b) | Initial notification /amendment | Initial notification |
| 3. | Details of the issuer | |
| a) | Name | Tiziana Life Sciences plc |
| b) | LEI | 213800CED47HI8PIOB36 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument | Ordinary Shares of 3p each |
| b) | Identification code of the Financial Instrument | ISIN for Tiziana Life Sciences plc: GB00BKWNZY55 |
| c) | Nature of the transaction | Exercise of options |
| d) | Price(s) and volume(s) | Price Volume (i) Gabriele Cerrone 35p 169,225 (ii) Keeren Shah 35p 5,000 |
| e) | Aggregated information - Aggregated volume - Price | 174,225 35 pence |
| f) | Date of the transaction | 23 October 2020 |
| g) | Place of the transaction | XLON |